# Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

> **NCT05718323** · PHASE2 · RECRUITING · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 44 (estimated)

## Conditions studied

- SCLC,Extensive Stage
- SLFN11-positive

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05718323
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718323, "Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05718323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*